📞  +1 (855) 661-4441(US)   📞  +44 1720 412 167(UK)

Hemophilia Treatment: Increasing awareness about hemophilia is projected to boost the market growth at a healthy CAGR of ~ 6.0% during the forecast period 2017-2023

"August 2022, Market Research Future has published a Report on the global Hemophilia Treatment market.

Market Highlights

According to the latest report published by Market Research Future (MRFR), the global market for hemophilia is set to surge at a CAGR of 6.10% between 2018 and 2023. The market is expected to reach a valuation in excess of USD 16,000 Mn by the year 2023. Hemophilia is an inherited genetic blood disorder and holds a chronic status. People with hemophilia are likely to live with the condition throughout their life but the effects can be greatly reduced with the help of several hemophilia drug and therapeutics. The prevalence of hemophilia has increased across the globe in recent years. A higher level of awareness and high healthcare expenditure are two major factors that are driving the growth of haemophilia treatment market in the advanced countries in Americas and Europe.

Growing used of recombinant products is also reflecting favourably on the global market for hemophilia treatment. Recombinant products are an alternative to plasma derived products and considered relatively safer. Hemophilia drugs that are manufactured using recombinant products have proteins that are derived from genetically engineered cell lines and thereby have minimum or zero risk of contaminations. Demand for recombinant products is expected to remain high during the forecast period. Such factors are expected to support the growth of the market as well. In addition, regions such as the Middle East & Africa (MEA) and Asia Pacific (APAC) are also presenting lucrative growth opportunities to market players.

Access Report @ Hemophilia Treatment Market: Segmental Analysis

MRFR’s report also includes an in-depth segmental analysis of the global market for haemophilia treatment based on type, treatment type, end user and region. On the basis of type, the market has been segmented into hemophilia A, hemophilia B, and hemophilia C. Of these, the hemophilia A segment will continue to hold the largest share of the market over 2023. The segment is projected to reach a valuation of more than USD 12,600 Mn towards the end of review period, reflecting a healthy CAGR. By treatment type, the market is segmented into plasma derived coagulation factor concentrate, recombinant coagulation factor concentrates, desmopressin, gene therapy and antifibrinolytic agents. The recombinant coagulation factor concentrates segment is expected to remain highly attractive during the assessment period. This is primarily owing to the high level of safety and efficacy offered by recombinant coagulation factor concentrates. In 2017, the segment stood at market valuation of USD 6,500 Mn. By end user, the market is segmented into hospitals & clinics, research organization and others. By the year 2023, the hospitals & clinics segment is expected to surpass a market valuation of USD 11,000, exhibiting an impressive CAGR of 6.53%.

Global Hemophilia Treatment Market:

Regional Analysis

Based on regions, the hemophilia treatment market has been segmented into Europe, Americas, Asia Pacific (APAC), and the Middle East & Africa (MEA). Currently, the Americas region holds the largest share of the global haemophilia treatment market and is likely to retain its dominant position in 2018 and beyond. North America in particular present significant growth opportunities to market owing to factors such as high healthcare expenditure and existence of an advanced healthcare system. Meanwhile, Europe has emerged as the second largest market for hemophilia treatment. Presence a large number prominent drug manufacture gives the Europe market an edge. The market in APAC is also expected to witness a healthy growth during the forecast period. Rapid growth of the healthcare sector and introduction of favourable policies are attracting market players towards the region.

Growth Hemophilia Treatment Market: Competitive Landscape

Bayer AG, Swedish Orphan Biovitrum AB, Pfizer Inc, Grifols International S.A, Octapharma, Baxter, F.Hoffmann-La Roche Ltd, CSL Behring, Novo Nordisk A/S, Kedrion, Sanofi and Shire are some of the key market participants mentioned in MRFR’s report.  


Leading companies partner with us for data-driven Insights
client_1 client_2 client_3 client_4 client_5 client_6 client_7 client_8 client_9 client_10
Kindly complete the form below to receive a free sample of this Report
Please fill in Business Email for Quick Response

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Report details
Base Year 2022
Companies Covered 15
Pages 158
Certified Global Research Member
Isomar fd.webp Wcrc 57.webp
Why Choose Market Research Future?
  • Vigorous research methodologies for specific market.
  • Knowledge partners across the globe
  • Large network of partner consultants.
  • Ever-increasing/ Escalating data base with quarterly monitoring of various markets
  • Trusted by fortune 500 companies/startups/ universities/organizations
  • Large database of 5000+ markets reports.
  • Effective and prompt pre- and post-sales support.
Tailored for You
  • Dedicated Research on any specifics segment or region.
  • Focused Research on specific players in the market.
  • Custom Report based only on your requirements.
  • Flexibility to add or subtract any chapter in the study.
  • Historic data from 2014 and forecasts outlook till 2040.
  • Flexibility of providing data/insights in formats (PDF, PPT, Excel).
  • Provide cross segmentation in applicable scenario/markets.